NLRP3 Modulator Compounds for Refractory Cancer Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with impaired NLRP3 signaling, such as refractory cancers, are inadequate in effectively modulating NLRP3 activity to enhance innate immune response.
Innovation Solution
Development of compounds that modulate NLRP3 activity, including agonists and partial agonists, to increase NLRP3 signaling and enhance innate immune activity, which can be administered alone or in combination with other cancer therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for refractory cancers, then treatment is simple and easy to administer, but the innate immune response is insufficient and treatment outcomes are poor
Solution Approach 1:
The patent introduces NLRP3 modulators as intermediary compounds that mediate between the existing immune system components and the cancer cells. These compounds specifically target and modulate the NLRP3 inflammasome pathway, which is deficient in refractory cancers, thereby enhancing innate immune response without requiring complete redesign of the treatment approach. The modulators act as bridges to restore proper immune signaling.
Solution Approach 2:
The patent applies parameter changes by modifying the activity level of NLRP3 signaling pathway through pharmacological intervention. The NLRP3 modulators adjust the signaling parameters (activation threshold, signal amplitude, duration) of the inflammasome pathway to optimal levels, converting the deficient immune response into an effective anti-tumor response while maintaining treatability.
2Reliability
If NLRP3 signaling is increased to enhance innate immune activity, then cancer treatment effectiveness improves, but the risk of excessive immune activation and inflammation increases
Solution Approach 1:
The patent employs partial action by using NLRP3 modulators that provide controlled, partial activation of the NLRP3 pathway rather than complete or excessive activation. This partial modulation is sufficient to overcome the deficiency in refractory cancers while staying below the threshold that would trigger harmful excessive immune responses. The modulators achieve therapeutic effect with sub-maximal activation levels.
Solution Approach 2:
The patent incorporates feedback mechanisms where the NLRP3 modulators respond to the actual state of inflammasome activation and adjust the signaling accordingly. The pathway includes natural feedback loops where activated inflammasomes regulate their own activity through cytokine release and cellular feedback signals, preventing uncontrolled immune activation while maintaining effective anti-tumor response.
Data Source
AI summary
The present invention provides compounds of Formula (I), wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).